David Westenberg
Stock Analyst at Piper Sandler
(4.14)
# 535
Out of 4,711 analysts
145
Total ratings
54.55%
Success rate
12.28%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKYA Akoya Biosciences | Reiterates: Overweight | $4 → $3 | $2.49 | +20.48% | 7 | Nov 19, 2024 | |
| NTRA Natera | Maintains: Overweight | $150 → $200 | $161.88 | +23.55% | 13 | Nov 18, 2024 | |
| TEM Tempus AI | Reiterates: Neutral | $40 → $70 | $35.54 | +96.96% | 2 | Nov 12, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $2 → $2.5 | $1.97 | +26.90% | 6 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Overweight | $195 → $185 | $136.02 | +36.01% | 14 | Nov 11, 2024 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $26 → $22 | $18.34 | +19.96% | 6 | Nov 11, 2024 | |
| EXAS Exact Sciences | Maintains: Overweight | $85 → $75 | $59.40 | +26.26% | 9 | Nov 11, 2024 | |
| CTKB Cytek Biosciences | Maintains: Overweight | $8 → $8.5 | $6.32 | +34.49% | 8 | Nov 11, 2024 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $6 → $7 | $6.39 | +9.55% | 11 | Nov 11, 2024 | |
| IDXX IDEXX Laboratories | Reiterates: Neutral | $520 → $435 | $412.26 | +5.52% | 9 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $165 | $153.10 | +7.77% | 5 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $235 → $240 | $228.61 | +4.98% | 2 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $195 → $210 | $164.84 | +27.40% | 11 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $34 | $31.67 | +7.36% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $12.04 | +45.35% | 9 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $11.63 | +37.58% | 8 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $16.41 | +21.88% | 7 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $2.19 | +36.99% | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $14.04 | - | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $44.84 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $50.73 | - | 1 | Nov 21, 2017 |
Akoya Biosciences
Nov 19, 2024
Reiterates: Overweight
Price Target: $4 → $3
Current: $2.49
Upside: +20.48%
Natera
Nov 18, 2024
Maintains: Overweight
Price Target: $150 → $200
Current: $161.88
Upside: +23.55%
Tempus AI
Nov 12, 2024
Reiterates: Neutral
Price Target: $40 → $70
Current: $35.54
Upside: +96.96%
Pacific Biosciences of California
Nov 11, 2024
Maintains: Neutral
Price Target: $2 → $2.5
Current: $1.97
Upside: +26.90%
Illumina
Nov 11, 2024
Maintains: Overweight
Price Target: $195 → $185
Current: $136.02
Upside: +36.01%
Fulgent Genetics
Nov 11, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $18.34
Upside: +19.96%
Exact Sciences
Nov 11, 2024
Maintains: Overweight
Price Target: $85 → $75
Current: $59.40
Upside: +26.26%
Cytek Biosciences
Nov 11, 2024
Maintains: Overweight
Price Target: $8 → $8.5
Current: $6.32
Upside: +34.49%
Adaptive Biotechnologies
Nov 11, 2024
Maintains: Overweight
Price Target: $6 → $7
Current: $6.39
Upside: +9.55%
IDEXX Laboratories
Nov 4, 2024
Reiterates: Neutral
Price Target: $520 → $435
Current: $412.26
Upside: +5.52%
Oct 28, 2024
Maintains: Neutral
Price Target: $150 → $165
Current: $153.10
Upside: +7.77%
Oct 28, 2024
Maintains: Neutral
Price Target: $235 → $240
Current: $228.61
Upside: +4.98%
Aug 14, 2024
Maintains: Overweight
Price Target: $195 → $210
Current: $164.84
Upside: +27.40%
Aug 13, 2024
Maintains: Overweight
Price Target: $30 → $34
Current: $31.67
Upside: +7.36%
Aug 6, 2024
Maintains: Neutral
Price Target: $17 → $18
Current: $12.04
Upside: +45.35%
Jul 1, 2024
Maintains: Neutral
Price Target: $19 → $16
Current: $11.63
Upside: +37.58%
Feb 26, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $16.41
Upside: +21.88%
Nov 13, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $2.19
Upside: +36.99%
Mar 5, 2020
Initiates: Buy
Price Target: n/a
Current: $14.04
Upside: -
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $44.84
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $50.73
Upside: -